NVV1 Stock Overview
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.86 |
| 52 Week High | US$10.19 |
| 52 Week Low | US$3.33 |
| Beta | 1.6 |
| 1 Month Change | -11.76% |
| 3 Month Change | 2.97% |
| 1 Year Change | -44.84% |
| 3 Year Change | -98.02% |
| 5 Year Change | -55.20% |
| Change since IPO | -93.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVV1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.6% | -5.1% | -2.0% |
| 1Y | -44.8% | -21.1% | -0.3% |
Return vs Industry: NVV1 underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: NVV1 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| NVV1 volatility | |
|---|---|
| NVV1 Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NVV1's share price has been volatile over the past 3 months.
Volatility Over Time: NVV1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
| NVV1 fundamental statistics | |
|---|---|
| Market cap | €534.52m |
| Earnings (TTM) | -€511.49m |
| Revenue (TTM) | €923.11m |
0.6x
P/S Ratio-1.0x
P/E RatioIs NVV1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVV1 income statement (TTM) | |
|---|---|
| Revenue | US$983.71m |
| Cost of Revenue | US$1.08b |
| Gross Profit | -US$94.76m |
| Other Expenses | US$450.30m |
| Earnings | -US$545.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.89 |
| Gross Margin | -9.63% |
| Net Profit Margin | -55.41% |
| Debt/Equity Ratio | -23.4% |
How did NVV1 perform over the long term?
See historical performance and comparison